How to determine post-RCHOP therapy for risk-tailored adult patients with diffuse large B-cell lymphoma,addition of maintenance rituximab or observation: multicenter experience |
| |
| Authors: | Bin-Tao?Huang mailto:huangbintao@sina.com" title=" huangbintao@sina.com" itemprop=" email" data-track=" click" data-track-action=" Email author" data-track-label=" " >Email author,Qing-Chun?Zeng,Jessica?Yu,Zhen?Xiao,Bing-Sheng?Li,Chun-Lai?Zhang,Hong-Bo?Ji |
| |
| Affiliation: | (1) Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical College, 1 TongDao Avenue North, 010059 Hohhot, People’s Republic of China;(2) Department of Medicine, The Affiliated Hospital of Guangdong Medical College, 524001 Zhanjiang, People’s Republic of China;(3) Department of Surgery, University of Colorado School of Medicine, Aurora, CO 80045, USA;(4) Huizhou Medicine Institute, 516003 Huizhou, People’s Republic of China;(5) Department of Medicine, The First People’s Hospital of Chenzhou, 423000 Chenzhou, People’s Republic of China;(6) Department of Medicine, Chifeng Municipal Hospital, 024000 Chifeng, People’s Republic of China |
| |
| Abstract: | ![]()
Background In international prognostic index (IPI) risk-tailored adult patients with diffuse large B-cell lymphoma (DLBCL), it is still unclear whether the addition of maintenance rituximab (MR) improves progression-free (PFS) and overall survival (OS), after RCHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. |
| |
| Keywords: | |
| 本文献已被 PubMed SpringerLink 等数据库收录！ |
|
